WASHINGTON (Reuters) - Drugmaker GlaxoSmithKline Plc said Thursday US regulators had approved an over-the-counter nicotine lozenge designed to help people quit smoking. (Who wants to QUIT!!) The Commit Lozenge helps relieve craving and nicotine withdrawal symptoms by providing a temporary alternative source of nicotine, the company said in a statement. The product also gives smokers a way to determine the appropriate strength of nicotine they need, based on how quickly they need to smoke after waking, the company said. The lozenges have been shown effective in helping people quit, including smokers who have tried quitting before, the company said....